Table 1.
Baseline characteristics (n = 751)
| Characteristics | n (%) |
|---|---|
| Age, median (IQR) | 43 (36–51) |
| Age groups | |
| 18–35 | 168 (22) |
| 36–50 | 392 (52) |
| ≥ 51 | 191 (25) |
| Sex | |
| Male | 503 (67) |
| Female | 242 (32) |
| Transgender | 6 (< 1) |
| Aboriginal/Torres Strait Islander identity | |
| Yes | 181 (24) |
| No | 563 (75) |
| Unknown | 7 (1) |
| Completed high school or higher education | |
| Yes | 214 (29) |
| No | 537 (71) |
| Main source of income | |
| No income | 21 (3) |
| Full-time/part-time/casual employment | 58 (8) |
| Government assistance | 637 (85) |
| Other | 35 (4) |
| Housing | |
| Stable | 522 (70) |
| Unstable | 229 (30) |
| Incarceration | |
| Never | 355 (47) |
| Ever (not in past 12 months) | 248 (20) |
| In past 12 months | 148 (33) |
| Injected drugs in past 6 months | |
| Yes | 541 (72) |
| No | 210 (28) |
| Injected drugs in past month | |
| Yes | 475 (63) |
| No | 276 (37) |
| Hazardous alcohol consumption (AUDIT-C)a | |
| Never drinks | 331 (44) |
| Low risk male/female | 160 (21) |
| High risk male/female | 254 (34) |
| Smoking stats | |
| Never | 35 (5) |
| Previous | 74 (10) |
| Current | 642 (85) |
| Opioid agonist therapy | |
| Current | 517 (69) |
| Previous, not current | 91 (12) |
| Never | 143 (19) |
| Self-reported HCV infection | |
| Negative | 222 (29) |
| Positive | 396 (53) |
| Unknown | 133 (18) |
| Previous/current HCV treatmentb | 81 (20) |
| HCV RNA test result | |
| Negative | 372 (50) |
| Positive | 323 (43) |
| Invalid/missing | 56 (7) |
| FibroScan® liver disease staging | |
| F0/F1—no/mild fibrosis | 514 (68) |
| F2—moderate fibrosis | 85 (11) |
| F3—severe fibrosis | 44 (6) |
| F4—cirrhosis | 63 (8) |
| Invalid | 34 (5) |
| Missing | 11 (1) |
aTransgender excluded from AUDIT-C (n = 6)
bAmong participants reporting having HCV infection (n = 396)